Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors

Chun-Han Lin, Fanny A. Pelissier, Hui Zhang, Jon Lakins, Valerie M. Weaver, Catherine Park, and Mark A. LaBarge

ABSTRACT Stiffness is a biophysical property of the extracellular matrix that modulates cellular functions, including proliferation, invasion, and differentiation, and it also may affect therapeutic responses. Therapeutic durability in cancer treatments remains a problem for both chemotherapies and pathway-targeted drugs, but the reasons for this are not well understood. Tumor progression is accompanied by changes in the biophysical properties of the tissue, and we asked whether matrix rigidity modulated the sensitive versus resistant states in HER2-amplified breast cancer cell responses to the HER2-targeted kinase inhibitor lapatinib. The antiproliferative effect of lapatinib was inversely proportional to the elastic modulus of the adhesive substrata. Down-regulation of the mechanosensitive transcription coactivators YAP and TAZ, either by siRNA or with the small-molecule YAP/TEAD inhibitor verteporfin, eliminated modulus-dependent lapatinib resistance. Reduction of YAP in vivo in mice also slowed the growth of implanted HER2-amplified tumors, showing a trend of increasing sensitivity to lapatinib as YAP decreased. Thus we address the role of stiffness in resistance to and efficacy of a HER2 pathway–targeted therapeutic via the mechanotransduction arm of the Hippo pathway.

INTRODUCTION Human epidermal growth factor receptor 2 (HER2)–positive breast cancers account for ∼15–20% of breast cancers, have poor prognosis, and are less responsive to hormone treatment than HER2(−) breast cancers (Kun et al., 2003; Koboldt et al., 2012). Although HER2-targeted therapies are one of the success stories in breast cancer treatment (Kim et al., 2013), generating a durable drug response remains a challenge (Rexer and Arteaga, 2012). The tyrosine kinase inhibitor lapatinib is a potent inhibitor of catalytic activity of both epidermal growth factor receptor (EGFR) and HER2 (Medina and Goodin, 2008). Most tumor cells with elevated HER2 levels show high sensitivity to growth inhibition by lapatinib, but resistance often develops (Rusnak et al., 2007).

Several mechanisms of lapatinib resistance have been reported, including compensatory activation of parts of the HER network. Compensatory up-regulation of HER3 activation, driven by Akt activity, confers resistance to lapatinib in HER2-amplified breast cancer...
cell lines (Amin et al., 2010). Incomplete inhibition of EGFR results in hereregulin-driven feedback, sustaining EGFR activation, which contributes to lapatinib resistance in HER2(+) breast cancers (Xia et al., 2013). Up-regulation of the membrane tyrosine kinase AXL sustains phosphoinositide 3-kinase (PI3K)/Akt signaling, conferring lapatinib resistance (Liu et al., 2009). Hepatocyte growth factor (HGF) activation of its cognate receptor MET also is associated with resistance to lapatinib in HER2(+) gastric cancers (Chen et al., 2012). Thus activation of redundant survival pathways can be induced, either intrinsically or extrinsically, by microenvironmental factors, such as growth factors.

The biophysical properties of tumors change during malignant progression, which also affects tumor cell functions. Thus, in addition to redundant signaling pathways, using integrin-blocking antibodies to alter how tumor cells perceived their microenvironments was shown to modulate the efficiency of cytotoxic agents (Weaver et al., 2002). Use of an in vitro approach that compared responses of a number of HER2-targeted therapeutics (including lapatinib) in multiple HER2-amplified cell lines revealed that some cells were more sensitive to lapatinib in three-dimensional (3D) Matrigel than with two-dimensional (2D) cultures using tissue culture plastic (TCP; Weigelt et al., 2010). Even in the relatively simplified 3D Matrigel cultures, there are multiple chemical and physical properties that contribute to those microenvironment-dependent drug responses. Accumulating evidence suggests that microenvironment rigidity can promote tumor progression and survival through activation of growth factor signaling pathways by enhancing integrin clustering and focal adhesion assembly (Paszek et al., 2014; Rubashkin et al., 2014) or through modulation of microRNA expression (Mouw et al., 2014). Tissue rigidity also affects cytotoxic chemotherapeutic responses in hepatocarcinoma cells because increasing matrix stiffness promotes cellular proliferation and resistance to chemotherapeutic agents (Schrader et al., 2011). Whereas this scenario is quite sensible in the context of cytotoxic chemotherapeutics, the effect of matrix rigidity on a HER2-targeted therapeutic such as lapatinib is less obvious.

Here we examined whether matrix rigidity affected lapatinib responses in HER2-amplified breast cancer cells, using polyacrylamide (PA) hydrogel–based culture substrates that enabled control over Young’s elastic modulus. The Hippo pathway mechanotransducers, transcriptional coactivator with PDZ-binding motif (TAZ) and Yes-associated protein (YAP) (Halder et al., 2012), which are also onco genes (Wang et al., 2012), were required for modulus-dependent responses in vitro. Down-regulation of YAP in vivo slowed HER2-amplified tumor growth and improved sensitivity to lapatinib. YAP and TAZ did not mediate resistance by redundant activation of other HER-family receptors. Our results suggest that rigid microenvironments can modulate lapatinib resistance in HER2-amplified breast cancer cells via a YAP/TAZ-dependent mechanism.

RESULTS
Substrate elastic modulus is a modifier of lapatinib responses in HER2-amplified breast cancer cells
To facilitate further investigation of microenvironment-directed drug responses, we identified a breast cancer cell line and pathway-targeted drug combination that offered a potentially wide dynamic range of response. Previous work demonstrated that the use of 2D TCP versus 3D Matrigel culture microenvironments modulated the antiproliferative responses of four different HER2-targeted therapeutics that were used to treat four different HER2-amplified breast cancer cell lines. The combination of HCC1569 cells, a basal A subtype cell line (Neve et al., 2006), and lapatinib demonstrated the optimal differential response between TCP and 3D Matrigel (Weigelt et al., 2010). We first validated our analysis methodology by showing that HER2-amplified HCC1569 breast cancer cells conformed to previous findings, that is, that they are more sensitive to the antiproliferative effect of lapatinib in 3D Matrigel than with cells on 2D TCP (Weigelt et al., 2010). After plating on type 1 collagen–coated 2D TCP or in 5% “on-top” 3D Matrigel, cells were treated with dimethyl sulfoxide (DMSO) or 1.5 μM lapatinib, a dose that was comparable to the average concentration in patient blood serum (Burris et al., 2005). The magnitude of the antiproliferative effect of lapatinib was determined by measuring 5-ethyl-2'-deoxyuridine (EdU) incorporation into nuclear DNA as a proxy for cell proliferation. Cells in 3D Matrigel were more sensitive to lapatinib than cells on TCP, with 21 ± 2.6 and 69 ± 9.7% EdU incorporation, respectively (Figure 1, A and B). Proliferation of the HER2-negative cell line BT549 was not affected by lapatinib treatment (Figure 1, A and B). The differential antiproliferative response between TCP and 3D Matrigel is partly explained by the distinct molecular compositions of the two culture microenvironments; indeed, it is known that the increased sensitivity in three dimensions is due partly to β1 integrin–mediated extracellular matrix adhesion (Weigelt et al., 2010). However, there are other potential microenvironment characteristics that bear scrutiny in this drug response context.

One of the major differences between TCP and 3D Matrigel is the rigidity of the culture substrate. Thus we examined whether rigidity is a modulator of responses to lapatinib in HER2-amplified breast cancer cells. Young’s elastic modulus of Matrigel has been estimated at 400 Pa (Soofi et al., 2009), on a par with that for normal breast tissue (Paszek et al., 2005). In contrast, the elastic modulus of TCP is >2 GPa (Sarwatani et al., 2005; Levental et al., 2007), which is well outside the physiological range (Kolahi et al., 2012). To examine the role played by matrix rigidity in lapatinib responses, cell culture substrates were fabricated from PA gels to 400 ± 160 Pa and coated with a type 1 collagen to support cell adhesion. HCC1569 cells were more sensitive to lapatinib on 400-Pa PA gels than on TCP coated with type 1 collagen, with 50 ± 4.5 and 69 ± 4.5% EdU incorporation, respectively (Figure 1, C and D); BT549 cells were not affected by lapatinib or changes in rigidity (Figure 1, C and D). The half-maximal inhibitory concentration (IC50) of lapatinib was threefold lower on 400-Pa PA gels than with TCP, 0.9 and 2.7 μM, respectively (Figure 1E). Thus HCC1569 cells responded to lapatinib in an elastic modulus–dependent manner, showing greater resistance to the antiproliferative effect of lapatinib on rigid matrices.

YAP and TAZ are required for the modulus-dependent lapatinib responses
YAP and TAZ are Hippo pathway transcriptional coactivators that interact with the Rho/Rock pathway (Halder et al., 2012) and play an important role in transducing information about substrate rigidity from the plasma membrane into the nucleus, where a transcriptional response is generated (Dupont et al., 2011). Consistent with their role in mechanotransduction, YAP and TAZ relocated from the cytoplasm into the nucleus as substrate stiffness increased (Figure 2, A and B). We assessed the effect of YAP and TAZ knockdown by small interfering RNA (siRNA) on modulus-dependent responses to lapatinib. Both YAP and TAZ knockdown (Supplemental Figure S1A) eliminated modulus-dependent lapatinib resistance on TCP (Figure 2C). Disruption of the TEAD-YAP interaction with 2 μg/ml inhibitor verteporfin (Liu-Chittenden et al., 2012) phenocopied the effect of YAP knockdown (Figure 2D). Indeed, increasing concentrations of verteporfin diminished the effect of modulus-dependent
Cells implanted in mice. Tumor volume was measured during the course of lapatinib treatment (Figure 3). Mice that received neither IPTG nor lapatinib (group A) had the maximum tumor volume (mean of volume, 1280 mm³) by day 23. Mice treated with IPTG (group B) had significantly decreased (p < 0.05) tumor volume (mean of volume, 770 mm³) compared with group A. Lapatinib treatment groups either with (group D) or without IPTG treatment (group C) had much smaller tumor volumes compared with groups A and B. Group D, which received lapatinib and had reduced YAP levels, had the smallest tumor volumes (mean of volume, 192 mm³), even compared with group C (mean of volume, 269 mm³); however, that difference was not statistically significant. These data demonstrate that YAP knockdown was sufficient to reduce growth of HER2-amplified cell lines in vivo, and they suggest that YAP knockdown and lapatinib together may have some synergistic benefit. More comprehensive animal studies are required, however, to clarify the independent versus synergistic effects.

Modulus-dependent lapatinib responses are driven by multiple factors

We sought to delineate other components of the molecular circuitry that enabled YAP to mediate the modulus-dependent response to lapatinib. Analysis of breast cancer data from the Cancer Genome Atlas (Koboldt et al., 2012) showed that YAP mRNA expression correlated positively with expression of two known YAP targets, CTGF and amphiregulin (AREG; Zhang et al., 2009), which is an EGFR ligand that has been attributed with multiple roles related to tumor invasion and drug resistance (Hurbin et al., 2002; Higginbotham et al., 2011; Supplemental Figure S3). HER2 (encoded by the ERBB2 gene) mRNA expression positively correlated with AREG and inversely correlated with EGFR and ERBB3 mRNA levels. Taken together, the results indicate that higher AREG expression correlated with YAP and HER2 expression in breast cancers.

We further examined AREG, which has been shown to mediate EGFR-HER3 heterodimer formation and activate the extracellular signal-regulated kinase (ERK)-Akt signaling pathway (Yotsumoto et al., 2010). In addition, HER3-mediated PI3K/Akt activity was correlated with lapatinib resistance in HER2-amplified breast cancer cells (Garrett et al., 2011). Paracrine AREG signaling in colorectal cancer cells also was shown to sustain ERK signaling and confer resistance to EGFR inhibitors (Hobor et al., 2014).

AREG mRNA levels in HCC1569 cells showed a modestly increasing trend as the culture substrate rigidity was increased (Figure 4A), lapatinib resistance in a synergistic manner with lapatinib (Supplemental Figure S2). YAP and TAZ were thus shown to be necessary for generating modulus-dependent lapatinib resistance.

YAP knockdown in vivo increased sensitivity to lapatinib treatment

To test whether YAP similarly played a role in lapatinib responses in vivo, we used isopropyl β-D-thiogalactopyranoside (IPTG)-induced short hairpin RNA (shRNA) to knock down YAP in HCC1569 cells.
but cell membrane surface AREG protein level increased only ∼4% (Figure 4B). To mimic the presence of a paracrine source of AREG, we added exogenous recombinant AREG (5 ng/ml) to cells, which caused increased nuclear YAP localization, even on compliant 400-Pa surfaces (Figure 4C), and on compliant surfaces conferred lapatinib resistance to the cells (Figure 4D). Simultaneous addition of exogenous AREG and the EGFR receptor inhibitor, erlotinib, reduced the resistance phenotype, demonstrating that exogenous AREG was exerting its effect partly through EGFR (Figure 4D). Knockdown of AREG by siRNA (siAREG) did not affect other ligands of EGFR, such as EGF or transforming growth factor-α, nor did it affect the receptors EGFR and HER2 (Supplemental Figure S1B). YAP knockdown with siRNA decreased AREG expression 25%, suggesting that YAP modulates AREG (Figure 4E). These data together suggest that AREG is putatively involved in the modulus-dependent lapatinib responses. However, direct targeting of AREG via siAREG showed no significant effect on modulus-dependent lapatinib responses (Figure 4F). Because AREG was reported to cause activation of HER3 (Yotsumoto et al., 2010), we examined modulus-dependent changes in HER3 phosphorylation at 1 and 48 h after attachment, as well as from 49 other receptor tyrosine kinases. Without lapatinib treatment, HER3 showed decreased phosphorylation within 1 h, and then HER3 showed a subtle increase in phosphorylation by 48 h on stiffer substrates (40 kPa). The results taken together show that modulus-dependent lapatinib resistance cannot be explained from a single YAP-AREG circuit.

**DISCUSSION**

Here we demonstrate that the mechanical property of microenvironments may influence resistance to and efficacy of the HER2 pathway–targeted therapeutic lapatinib in HER2-amplified breast cancer cells. Although engineered culture substrates necessarily oversimplify the tumor microenvironment compared with in vivo, they can reveal important mechanistic elements of cellular responses by winnowing down the possible candidate pathways involved in a given response. We specifically probed the property of elastic modulus on cells at low density on PA gels to minimize the confounding effects of cell–cell contact. YAP activation is regulated also by cell–cell contact (Zhao et al., 2007); high cell density inhibits YAP activation by inducing YAP phosphorylation. In our engineered system, YAP and TAZ activation correlated with resistance to lapatinib, and when YAP was knocked out in orthotopically implanted tumors grown in mice, tumor growth slowed and they became more sensitive to lapatinib. The resistance phenotype is not exclusively modulus dependent, but by isolating and studying that one physical property of the matrix, we showed that the Hippo pathway is likely an important component of resistance in HER2-targeted kinase inhibitors.

YAP has been attributed dual roles in tumor genesis in breast cancer. Studies in vitro show that exogenous expression of YAP in cells can promote cell growth, suggesting that YAP has a role as a tumor promoter (Wang et al., 2012). Others studies reported potential tumor-suppressive roles for YAP. Loss of heterozygosity at the YAP locus in a number of luminal breast cancers and shRNA knockdown of YAP in some breast cancer cell lines suppress anoikis and promotes tumor growth in vivo (Yuan et al., 2008). Moreover, YAP expression was reduced in some invasive carcinoma samples compared with normal breast tissues (Tufail et al., 2012). The multiple roles of YAP in tumorigenesis may depend on the stage of progression of a given cell; for example, active YAP enhances tumor growth when expressed in mammary carcinomas but not when expressed in a nonmalignant mammary epithelial cell line (Lamar et al., 2012). YAP expression in breast cancers may be subtype dependent (Kim et al., 2014), and YAP is notably present in stromal...
cells (Calvo et al., 2013) and not only epithelial cells, which further complicates the in vivo situation. In addition, YAP and TAZ exhibit distinct functions; for example, YAP-knockout mice are embryonic lethal (Morin-Kensicki et al., 2006), but TAZ- knockout mice can be viable, although the animals have kidney disease (Hossain et al., 2007). Here we showed that either YAP or TAZ knockdown in vitro can eliminate modulus-dependent lapatinib responses and confer more sensitivity to lapatinib, suggesting redundant roles in the context of modulus-dependent response to lapatinib.

The photosensitizer verteporfin (Visudyne; Novartis, Basel, Switzerland) is used as photodynamic therapy for neovascular lesions in the eye (Michels and Schmidt-Erfurth, 2001). In the absence of photobleaching, verteporfin can disrupt TEAD-YAP association and inhibit YAP transcriptional activities (Yamada et al., 2008), but the tumor microenvironment will likely play an important role as well. Indeed, greater matrix rigidity leads to increased resistance to the antiproliferative effects of lapatinib in HER2-amplified breast cancer cells on culture substrates engineered to mimic different levels of matrix rigidity. Several studies have shown in various cancer contexts that increasing matrix stiffness can both promote chemotherapeutic resistance (Schrader et al., 2011; Sharma et al., 2014; Zustiak et al., 2014) and decrease sensitivity to Raf kinase inhibitors (Nguyen et al., 2014); however, the mechanisms underlying these elastic modulus–dependent effects are not well defined.

Lapatinib resistance also has been linked to compensatory activation of HER3 (Amin et al., 2010), but we did not find that HER3 was strongly activated in the context of increased matrix rigidity. To mimic levels found in patient serum, we used 1.5 μM lapatinib, a concentration considered high (Amin et al., 2010), and measured HER3 phosphorylation 48 h after lapatinib treatment, whereas compensatory activation of HER3 may occur after 72 h and at a lower lapatinib concentration. Taken together, and experimental differences notwithstanding, these reports suggest that resistance to HER2-targeted kinase inhibitors is likely a multifaceted challenge still to be overcome.

That most failures in drug development are due to a lack of efficacy suggests that our preclinical development toolbox does a poor job of predicting compound activity in vivo (Baker and Chen, 2012). Multwell TCP plates are still the substrate of choice for much of modern drug screening, which ignores an obvious lack of context (Labarge et al., 2014). Some high throughput (HT)–compatible 3D culture systems are being developed to overcome this problem, but retooling of HT systems and improvements in image analysis algorithms remain significant barriers to wide-scale adoption. Adaptation of 2D hydrogels that are controlled for tissue-like elastic moduli and are conjugated with tissue-like molecular milieus to HT systems might present an intermediate step that can both take advantage of existing HT systems and recapitulate some key elements of in vivo microenvironments that are crucial for determinants of drug responses.

Our data show that microenvironment rigidity influenced lapatinib responses in HER2-amplified breast cancer cell lines and that YAP and TAZ are important in this context. Our findings underscore the importance of microenvironmental effects in drug development and suggest potential therapeutic benefits of verteporfin in HER2-targeted treatment.

**MATERIALS AND METHODS**

**Cell culture and drug treatment**

HCC1569 (American Type Culture Collection, Manassas, VA) and BT549 breast cancer cell lines (a gift from Joe W. Gray, Oregon Health and Science University, Portland, OR) were maintained in RPMI 1640 (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (FBS; Gemini Bio-Products, West Sacramento, CA), and 1% penicillin/streptomycin/glutamine (Invitrogen). Genotypes of the cell lines were authenticated by STR profiling (DDC Medical, Fairfield, OH).

For drug treatment in 2D cultures, cells were cultured in 24-well plates with RPMI 1640 with 1% FBS and 1% penicillin/streptomycin/glutamine for 48 h after initial adhesion and then treated with lapatinib (1.5 μM; LC Laboratories, Woburn, MA) for an additional 48 h. For drug treatment in 3D cultures, cells were cultured in 24-well plates coated with Matrigel (BD Biosciences, San Jose, CA) following the so-called “on-top” protocol adapted from Lee et al. (2007), using a 5% Matrigel drip, and then drugs or control were added on day 4 after cell plating for an additional 48 h. Other pharmaceutical and recombinant protein modulators were added concurrently with lapatinib: verteporfin (Sigma-Aldrich, St. Louis, MO) was added at
Drug response values are expressed as a percentage of DMSO-treated cells.

Transfection
Cells were transfected with YAP, WWTR1 (TAZ), AREG, or nonsilencing control siRNA (NSC; SMARTpool: ON-TARGET plus, GE Dharmacon, Lafayette, CO) with a fluorescein isothiocyanate label (siGLO Green Transfection Indicator; GE Dharmacon), using DharmaFECT 2 Transfection Reagent (GE Dharmacon) according to the manufacturer’s protocol 72 h before assay performance.

Immunofluorescence staining
Cells were fixed in 4% paraformaldehyde at room temperature for 10 min, blocked with PBS, 5% normal goat serum, and 0.1% Triton X-100 at room temperature for 30 min, and then incubated with primary antibodies anti-YAP (1:100; Santa Cruz Biotechnology, Dallas, TX) and anti-TAZ (1:200; Cell Signaling Technology, Beverly, MA) overnight at 4°C. Primary antibodies were visualized with fluorescent secondary antibodies raised in goats (1:500; Invitrogen) together with Hoechst 33342 (1:200; Sigma-Aldrich) incubated at room temperature for 2 h. Images were acquired with a Zeiss 710 LSM confocal microscope. Cell segmentation and single-cell fluorescence intensities were analyzed with Matlab script adapted from Pelissier et al., 2014. For quantification of YAP/TAZ localization, the ratios of mean fluorescence intensity in the cytoplasmic (C) and nuclear (N) compartments of segmented cells were used. The cutoffs of log₂ ratios were used to establish three classes: C > N (X < −0.074), N = C (−0.074 < X < 0.074), and N > C (X > 0.074).

Real-Time PCR
Total RNA was extracted with TRIzol (Invitrogen) and purified by RNeasy prep (Qiagen, Valencia, CA). cDNA was synthesized with SuperScript III RT (Invitrogen). Transcripts levels were measured by quantitative real-time PCR (qRT-PCR) with iTaq SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA) and Light Cycler480 (Roche, Indianapolis, IN). Primer sequences were as follows: YAP, 5′-AGCCAGTTGCACTTCAACAG-3′ and 5′-GGGAGAAAACGCAGGACAAAC-3′; TAZ (WWTR1), 5′-AGCAGCAATGGACAAACCTG-3′ and 5′-TGCATTGAGGGGGATCAG-3′; AREG, 5′-GTGGGTGTGTGCCTCTTGATA-3′ and 5′-ACTCAAAGGGAAATCTCACT-3′; and glyceraldehyde-3-phosphate dehydrogenase, 5′-AAGGTGAACTCACAGGGGAAATCTCACT-3′ and 5′-GTGGTGCTAAGGCTTCAAC-3′. Real-time PCR was performed using DharmaFECT 2 Transfection Reagent (GE Dharmacon) according to the manufacturer’s protocol 72 h before assay performance.

Flow cytometry
Cells were collected via EDTA-PBS (0.4% EDTA) treatment without trypsin on ice. After washing with PBS, cells were blocked with PBS containing 2% bovine serum albumin, 5% normal goat serum, and 5 mM EDTA on ice for 30 min. Cells were incubated with the primary antibody anti-AREG (1:100; R&D Systems, Minneapolis, MN) on ice for 30 min, washed with PBS, and then treated with the secondary antibody anti-YAP (1:100; Santa Cruz Biotechnology, Dallas, TX) and anti-TAZ (1:200; Cell Signaling Technology, Beverly, MA) overnight at 4°C. Primary antibodies were visualized with fluorescent secondary antibodies raised in goats (1:500; Invitrogen) together with Hoechst 33342 (1:200; Sigma-Aldrich) incubated at room temperature for 2 h. Images were acquired with a Zeiss 710 LSM confocal microscope. Cell segmentation and single-cell fluorescence intensities were analyzed with Matlab script adapted from Pelissier et al., 2014. For quantification of YAP/TAZ localization, the ratios of mean fluorescence intensity in the cytoplasmic (C) and nuclear (N) compartments of segmented cells were used. The cutoffs of log₂ ratios were used to establish three classes: C > N (X < −0.074), N = C (−0.074 < X < 0.074), and N > C (X > 0.074).
antibody on ice for 15 min. After two PBS washes, the level of AREG bound on cell membrane was measured with a FACSCalibur (Becton-Dickinson, San Jose, CA).

**AREG enzyme-linked immunosorbent assay**

The intracellular AREG protein level was measured according to the manufacturer's protocol (Abcam, Cambridge, MA), after 72 h in HCC1569 cells cultured on 2D TCP and 400-Pa PA gel with YAP knockdown by siRNA or nonsilencing control.

**Animal experiments**

Six-week-old female nu−/− mice were obtained from Taconic (Germantown, NY) and housed five per cage with chow and water ad libitum in a controlled animal barrier. After 1 wk, the animals were injected subcutaneously into the upper flank with (3.5–5) × 106 shRNA YAP HCC1569 cells. On day 13 after tumor injection, when the average tumor volume was 150–200 mm3, IPTG (Sigma-Aldrich) and lapatinib were administered for 2 wk. IPTG was mixed into the drinking water at 10 mM/1% glucose in light-protected bottles and changed every 2–3 d. Lapatinib was administered at 75 mg/kg/day body weight divided into twice-daily dosing by oral gavage. Tumor dimensions (width, height, and depth) were measured biweekly. At the time of killing, tumors were harvested and either immediately snap frozen or fixed in Formalin. Animals were monitored for toxicity by measuring weight, assessing overall activity, and performing necropsy. All experimental procedures were followed according to the University of California, San Francisco, Animal Welfare Committee’s approved policies and guidelines.

**Human phospho–receptor tyrosine kinase array**

HCC1569 cells were cultured on 400-Pa and 40-kPa PA gels for 48 h, treated with lapatinib (1.5 μM) or DMSO, and then harvested at 1 or 48 h after lapatinib treatment. The phosphorylations of 49 different receptor tyrosine kinases were measured according to the manufacturer’s protocol (ARY001B, lot 1323072; R&D Systems).

**Statistics**

Significance was considered p < 0.05 or better using t tests and Pearson correlations. Those tests and area-under-the-curve calculations were performed with Prism (GraphPad, La Jolla, CA). *p < 0.05, **p < 0.01, and ***p < 0.001.

**ACKNOWLEDGMENTS**

M.L. is supported by National Institutes of Health Grants NIA R00AG033176 and R01AG040081, the U.S. Department of Energy (DE-AC02-05CH11231), a Congressionally Directed Medical Research Programs/Breast Cancer Research Program Era of Hope Scholar Award, and the California Breast Cancer Research Program and Anita Tarr Turk Fund for Breast Cancer Research (2018-0109).

**REFERENCES**


